Sera Prognostics (SERA) Non-Current Deffered Revenue (2020 - 2021)

Sera Prognostics (SERA) posted Non-Current Deffered Revenue of $35000.0 for Q3 2021, down 82.5% on a QoQ basis from $200000.0 in Q2 2021.

Sera Prognostics (SERA) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends

Sera Prognostics' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $35000.0 for Q3 2021.

Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $35000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $35000.0 (changed N/A YoY) and the FY2020 annual result came in at $300000.0, changed N/A from the prior year.
Non-Current Deffered Revenue was $35000.0 for Q3 2021 at Sera Prognostics, down from $200000.0 in the prior quarter.
Across five years, Non-Current Deffered Revenue topped out at $300000.0 in Q4 2020 and bottomed at $35000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Abbott Laboratories	180.89 Bn	173.59 Bn	6.27 Bn	-
2	Stryker	127.82 Bn	124.94 Bn	3.81 Bn	-
3	Medtronic	107.49 Bn	98.27 Bn	6.41 Bn	-
4	Boston Scientific	67.24 Bn	65.78 Bn	3.61 Bn	-
5	Edwards Lifesciences	48.02 Bn	44.34 Bn	1.29 Bn	-
6	Dexcom	28.25 Bn	27.14 Bn	750.30 Mn	-
7	GE HealthCare Technologies	28.17 Bn	25.89 Bn	1.98 Bn	-
8	Smith & Nephew	26.72 Bn	26.14 Bn	-	-
9	Koninklijke Philips	25.31 Bn	22.19 Bn	2.07 Bn	512.79 Mn
10	Sera Prognostics	103.03 Mn	103.03 Mn	-28,000.00	-

Download Data